vs
Side-by-side financial comparison of Cue Biopharma, Inc. (CUE) and Idaho Strategic Resources, Inc. (IDR). Click either name above to swap in a different company.
Cue Biopharma, Inc. is the larger business by last-quarter revenue ($21.9M vs $14.6M, roughly 1.5× Idaho Strategic Resources, Inc.). Idaho Strategic Resources, Inc. runs the higher net margin — 64.3% vs 7.2%, a 57.1% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 92.0%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs 57.2%).
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
Idaho Strategic Resources, Inc.IDREarnings & Financial Report
Idaho Strategic Resources, Inc. is a U.S.-based natural resource company focused on the exploration, development, and production of critical and strategic minerals. Primarily operating in Idaho, it targets rare earth elements, gold, silver, and other high-demand minerals, supplying products to the clean energy, defense, and industrial manufacturing sectors across North America.
CUE vs IDR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.9M | $14.6M |
| Net Profit | $1.6M | $9.4M |
| Gross Margin | — | 68.5% |
| Operating Margin | 9.0% | 62.4% |
| Net Margin | 7.2% | 64.3% |
| Revenue YoY | 1292.3% | 92.0% |
| Net Profit YoY | 116.7% | 220.6% |
| EPS (diluted) | $0.05 | $0.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.9M | $14.6M | ||
| Q3 25 | $2.1M | $11.1M | ||
| Q2 25 | $3.0M | $9.5M | ||
| Q1 25 | $421.0K | $7.3M | ||
| Q4 24 | $1.6M | $7.6M | ||
| Q3 24 | $3.3M | $6.2M | ||
| Q2 24 | $2.7M | $6.1M | ||
| Q1 24 | $1.7M | $5.9M |
| Q4 25 | $1.6M | $9.4M | ||
| Q3 25 | $-7.4M | $3.0M | ||
| Q2 25 | $-8.5M | $2.8M | ||
| Q1 25 | $-12.3M | $1.6M | ||
| Q4 24 | — | $2.9M | ||
| Q3 24 | $-8.7M | $1.6M | ||
| Q2 24 | $-10.2M | $2.2M | ||
| Q1 24 | $-12.3M | $2.2M |
| Q4 25 | — | 68.5% | ||
| Q3 25 | — | 63.6% | ||
| Q2 25 | — | 57.8% | ||
| Q1 25 | — | 50.8% | ||
| Q4 24 | — | 53.3% | ||
| Q3 24 | — | 48.7% | ||
| Q2 24 | — | 50.2% | ||
| Q1 24 | — | 48.1% |
| Q4 25 | 9.0% | 62.4% | ||
| Q3 25 | -353.4% | 23.4% | ||
| Q2 25 | -292.3% | 26.6% | ||
| Q1 25 | -2921.4% | 19.3% | ||
| Q4 24 | — | 36.2% | ||
| Q3 24 | -264.2% | 23.4% | ||
| Q2 24 | -390.6% | 34.2% | ||
| Q1 24 | -737.8% | 36.3% |
| Q4 25 | 7.2% | 64.3% | ||
| Q3 25 | -346.6% | 26.8% | ||
| Q2 25 | -287.1% | 29.2% | ||
| Q1 25 | -2911.4% | 22.1% | ||
| Q4 24 | — | 38.5% | ||
| Q3 24 | -259.6% | 25.8% | ||
| Q2 24 | -382.7% | 35.2% | ||
| Q1 24 | -719.1% | 36.8% |
| Q4 25 | $0.05 | $0.62 | ||
| Q3 25 | $-0.07 | $0.20 | ||
| Q2 25 | $-0.09 | $0.20 | ||
| Q1 25 | $-0.17 | $0.12 | ||
| Q4 24 | — | $0.21 | ||
| Q3 24 | $-0.17 | $0.12 | ||
| Q2 24 | $-0.20 | $0.17 | ||
| Q1 24 | $-0.25 | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.1M | — |
| Total DebtLower is stronger | — | $2.3M |
| Stockholders' EquityBook value | $26.4M | $108.2M |
| Total Assets | $42.2M | $116.2M |
| Debt / EquityLower = less leverage | — | 0.02× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.1M | — | ||
| Q3 25 | $11.7M | — | ||
| Q2 25 | $27.5M | — | ||
| Q1 25 | $13.1M | — | ||
| Q4 24 | $22.5M | — | ||
| Q3 24 | $32.4M | — | ||
| Q2 24 | $30.0M | $6.3M | ||
| Q1 24 | $41.0M | $5.3M |
| Q4 25 | — | $2.3M | ||
| Q3 25 | — | $3.0M | ||
| Q2 25 | — | $3.3M | ||
| Q1 25 | — | $3.7M | ||
| Q4 24 | — | $1.7M | ||
| Q3 24 | $1.0M | $2.9M | ||
| Q2 24 | $2.0M | $2.7M | ||
| Q1 24 | $3.0M | $3.3M |
| Q4 25 | $26.4M | $108.2M | ||
| Q3 25 | $13.2M | $74.3M | ||
| Q2 25 | $18.2M | $49.3M | ||
| Q1 25 | $6.6M | $39.8M | ||
| Q4 24 | $17.5M | $37.7M | ||
| Q3 24 | $25.4M | $33.1M | ||
| Q2 24 | $21.6M | $25.4M | ||
| Q1 24 | $30.0M | $21.6M |
| Q4 25 | $42.2M | $116.2M | ||
| Q3 25 | $31.6M | $83.1M | ||
| Q2 25 | $40.7M | $57.7M | ||
| Q1 25 | $22.3M | $48.1M | ||
| Q4 24 | $32.2M | $44.0M | ||
| Q3 24 | $44.8M | $40.8M | ||
| Q2 24 | $42.3M | $32.2M | ||
| Q1 24 | $54.0M | $28.7M |
| Q4 25 | — | 0.02× | ||
| Q3 25 | — | 0.04× | ||
| Q2 25 | — | 0.07× | ||
| Q1 25 | — | 0.09× | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | 0.04× | 0.09× | ||
| Q2 24 | 0.09× | 0.11× | ||
| Q1 24 | 0.10× | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $10.7M |
| Free Cash FlowOCF − Capex | — | $8.2M |
| FCF MarginFCF / Revenue | — | 56.0% |
| Capex IntensityCapex / Revenue | 0.0% | 17.7% |
| Cash ConversionOCF / Net Profit | -0.68× | 1.15× |
| TTM Free Cash FlowTrailing 4 quarters | — | $12.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.1M | $10.7M | ||
| Q3 25 | $-9.0M | $2.4M | ||
| Q2 25 | $-3.4M | $3.5M | ||
| Q1 25 | $-8.2M | $2.4M | ||
| Q4 24 | $-36.3M | $3.2M | ||
| Q3 24 | $-7.5M | $2.5M | ||
| Q2 24 | $-10.0M | $2.6M | ||
| Q1 24 | $-9.8M | $2.6M |
| Q4 25 | — | $8.2M | ||
| Q3 25 | — | $709.8K | ||
| Q2 25 | $-3.4M | $2.5M | ||
| Q1 25 | $-8.3M | $1.0M | ||
| Q4 24 | $-36.4M | $2.1M | ||
| Q3 24 | $-7.5M | $1.9M | ||
| Q2 24 | $-10.0M | $2.4M | ||
| Q1 24 | $-9.8M | $2.3M |
| Q4 25 | — | 56.0% | ||
| Q3 25 | — | 6.4% | ||
| Q2 25 | -116.5% | 26.5% | ||
| Q1 25 | -1976.7% | 13.8% | ||
| Q4 24 | -2309.3% | 28.0% | ||
| Q3 24 | -225.7% | 30.4% | ||
| Q2 24 | -376.2% | 38.7% | ||
| Q1 24 | -573.0% | 38.3% |
| Q4 25 | 0.0% | 17.7% | ||
| Q3 25 | 0.0% | 15.3% | ||
| Q2 25 | 0.9% | 10.8% | ||
| Q1 25 | 35.6% | 19.4% | ||
| Q4 24 | 4.2% | 13.6% | ||
| Q3 24 | 0.0% | 9.8% | ||
| Q2 24 | 0.4% | 4.3% | ||
| Q1 24 | 3.2% | 5.5% |
| Q4 25 | -0.68× | 1.15× | ||
| Q3 25 | — | 0.81× | ||
| Q2 25 | — | 1.28× | ||
| Q1 25 | — | 1.50× | ||
| Q4 24 | — | 1.08× | ||
| Q3 24 | — | 1.56× | ||
| Q2 24 | — | 1.22× | ||
| Q1 24 | — | 1.19× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
IDR
Segment breakdown not available.
